title: (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
abstract: A number of new 1,4-benzodiazepin-2-one-based gastrin/CCK-B receptor antagonists related to the archetypal analogue L-365,260, and more closely to the recently reported compound YM022, have been synthesized and evaluated for biological activity. The compounds were screened for their ability to inhibit the binding of [125I]CCK-8 to gastrin/CCK-B receptors prepared from rat brains and that of [3H]L-364,718 to CCK-A receptors from rat pancreas, and were shown to be potent and selective ligands for the gastrin/CCK-B receptor. Functional studies in vivo demonstrated the compounds to be antagonists of the receptor as evidenced by their ability to inhibit pentagastrin-induced gastric acid secretion in anesthetized rats. More extensive evaluation in vivo included determination of ED50 values in the rat acid secretion model for selected compounds and an examination of the effect of these compounds on pentagastrin-induced gastric acid secretion in Heidenhain pouch dogs following oral and intravenous administration. Two compounds, i.e. (3R)-N-[1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyri dyl) -1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N-[1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5- (2-pyridyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl ]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21nmol/kg po in dogs. 15c is currently under clinical investigation for the treatment of gastro-oesophagal reflux disease (GORD).
authors.affiliation: Ferring Research Institute, Chilworth Research Centre, Chilworth, Southampton, U.K.
authors.forename: G
authors.initials: G
authors.lastname: Semple
authors.forename: H
authors.initials: H
authors.lastname: Ryder
authors.forename: D P
authors.initials: DP
authors.lastname: Rooker
authors.forename: A R
authors.initials: AR
authors.lastname: Batt
authors.forename: D A
authors.initials: DA
authors.lastname: Kendrick
authors.forename: M
authors.initials: M
authors.lastname: Szelke
authors.forename: M
authors.initials: M
authors.lastname: Ohta
authors.forename: M
authors.initials: M
authors.lastname: Satoh
authors.forename: A
authors.initials: A
authors.lastname: Nishida
authors.forename: S
authors.initials: S
authors.lastname: Akuzawa
authors.forename: K
authors.initials: K
authors.lastname: Miyata
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001569:Benzodiazepines / Q000494:pharmacology; D001570:Benzodiazepinones / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism; D020109:Devazepide; D004285:Dogs; D005744:Gastric Acid / Q000378:metabolism; D006727:Hormone Antagonists / Q000138:chemical synthesis / Q000494:pharmacology*; D015394:Molecular Structure; D010179:Pancreas / Q000378:metabolism; D010418:Pentagastrin / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding; D051381:Rats; D017207:Rats, Sprague-Dawley; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012844:Sincalide / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: D001570:Benzodiazepinones; D006727:Hormone Antagonists; D010671:Phenylurea Compounds; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D001569:Benzodiazepines; C087260:YM 022; C058121:L 365260; D010418:Pentagastrin; C104428:YF 476; D020109:Devazepide; D012844:Sincalide